论文部分内容阅读
目的:探讨地塞米松联合左甲状腺素治疗伴亚临床甲减(SCH)的桥本甲状腺炎(HT)的临床疗效。方法:将我院收治的300例SCH伴HT患者随机分为观察组和对照组(各150例),对照组单用左甲状腺素钠,观察组在对照组基础上加用地塞米松,比较两组的治疗效果。结果:治疗后,两组患者的FT4、FT3水平均较治疗前显著升高,STSH、TGAb、TPOAb、甲状腺体积均较治疗前显著降低(P<0.05);观察组治疗1年后的TGAb、TPOAb、甲状腺体积均显著低于对照组,P<0.05。结论:地塞米松联合左甲状腺素钠治疗SCH伴HT具有显著疗效,值得推广。
Objective: To investigate the clinical efficacy of dexamethasone combined with levothyroxine in the treatment of Hashimoto’s thyroiditis (HT) with subclinical hypothyroidism (SCH). Methods: Three hundred patients with HT and SCH who were treated in our hospital were randomly divided into observation group and control group (150 cases each). The control group was given levothyroxine alone. The observation group was treated with dexamethasone on the basis of the control group. Group treatment effect. Results: After treatment, the levels of FT4 and FT3 in both groups were significantly higher than those before treatment, and the levels of STSH, TGAb, TPOAb and thyroid were significantly lower than those before treatment (P <0.05) TPOAb, thyroid volume were significantly lower than the control group, P <0.05. Conclusion: Dexamethasone combined with levothyroxine in the treatment of SCH with HT has a significant effect and is worth promoting.